JACC Advances · Nov 16, 2026
Atrial Fibrillation Screening-to-Anticoagulation Pathways in Low- and Middle-Income Countries
By Jamileh E, Muhammad F, Farooq O et al.
Background Atrial fibrillation (AF) is an important cause of preventable stroke in low- and middle-income countries (LMICs), where diagnostic and treatment gaps may limit screening effectiveness. Objectives This study aims to evaluate AF screening in LMICs as a screening-to-anticoagulation pathway, focusing on reach, equity, diagnostic confirmation, anticoagulation uptake, and health-system capacity. Methods MEDLINE via PubMed, Embase, CINAHL, Web of Science, and CENTRAL were searched from inception to July 2026. LMIC studies reporting population-facing AF screening or screening-linked care were included. Logit-transformed proportions were pooled using restricted maximum-likelihood random-effects models with modified Hartung-Knapp CIs; binomial-normal generalized linear mixed models were used in sensitivity analyses. Pathway stages were synthesized from outcome-specific study subsets rather than a single longitudinal cohort. Results Thirty-seven reports from 13 LMICs and 1 multinational cohort were included. Across 22 community- or population-based studies, confirmed AF averaged 1.24% (95% CI: 0.79%-1.94%; I² = 98.8%; 95% prediction interval: 0.16%-8.83%). Newly detected AF averaged 0.95% (95% CI: 0.43%-2.11%; I² = 99.2%; prediction interval: 0.08%-9.97%). In separate study subsets, prior AF awareness was 50.7%, study-defined high stroke risk or oral anticoagulation indication was 78.9%, and oral anticoagulation coverage among study-defined eligible/high-risk participants was 22.8%. Reach ranged from 9.7% to 98.8%, and confirmation completion was 57.5% to 61.8% in 2 programs. Conclusions AF screening in LMICs identifies substantial but highly variable detection and treatment gaps. Pooled proportions should be interpreted as cross-study summaries rather than expected rates for a specific setting. Effective programs require representative reach, timely confirmation, appropriate stroke-risk and valvular assessment, access to anticoagulation, and longitudinal follow-up.
doi.org/10.1016/j.jacadv.2026.103479Open accessPubMed 43038801Interventions